$NPCE

Analysts made several rating changes: BTIG upgraded Etsy to Buy with a $90 target, JPMorgan upgraded Tyson Foods to Overweight with a $63 target, Mizuho initiated Boyd Group as Outperform with a $120 target, TD Cowen upgraded Targa Resources to Buy with a $350 target, Barclays initiated Tower Semiconductor as Overweight, Stifel upgraded Yeti to Buy with a $50 target, Citi upgraded Stubhub to Buy, KeyBanc initiated NeuroPace as Overweight, UBS upgraded Waste Connections to Buy, Bank of America in

NeuroPace (NPCE) reported Q2 2026 EPS loss of 18 cents, better than the Zacks Consensus by 5.3%. Revenue rose 17.1% to $22.8 million, with RNS revenue up 21.3% to $22.5 million. Cash and short-term investments were $51.7 million. Full-year 2026 revenue guidance was raised to $99.5-$101.5 million.

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which a

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NeuroPace Inc false 0001528287 0001528287 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report

NeuroPace Inc's CFO, Patrick F. Williams, has received equity compensation awards comprising 16,820 restricted stock units (RSUs) and stock options for 44,800 shares. These awards, detailed in a recent Form 4 filing, are part of his compensation and are not open-market transactions. The RSUs and stock options have specific vesting schedules, with initial vesting in May 2027 and subsequent installments designed to align the CFO's long-term incentives with the company's performance.

NeuroPace (NPCE) reported Q4 2025 revenue of US$26.6 million and an EPS loss of US$0.08, with trailing twelve-month revenue at US$100.0 million and an EPS loss of US$0.66. While revenue is growing and losses are narrowing, the company remains unprofitable, leading to a tension between bullish expectations for future growth and current valuation metrics. The stock trades at a P/S premium compared to the industry and peers, and above its DCF fair value, prompting caution despite analyst growth projections.

NeuroPace, Inc. announced it will report its financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. A conference call and webcast will follow at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) for investors to participate and listen to the discussion. The webcast will be archived on the company's investor relations website for replay.

Image source: The Motley Fool.Tuesday, Nov. 4, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

NeuroPace (NPCE) delivered earnings and revenue surprises of +45.00% and +11.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

NeuroPace ( NASDAQ:NPCE ) , a medical technology company known for its brain-responsive neuromodulation device for drug-resistant epilepsy, published its second quarter results on August 12, 2025. NeuroPace reported record GAAP revenue of $23.5 million, exceeding the analyst consensus of $23.09 ...